Document Detail

Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
MedLine Citation:
PMID:  3315605     Owner:  NLM     Status:  MEDLINE    
An anisoylated plasminogen streptokinase activator complex (APSAC) has been administered as a bolus intravenous injection of 30U to 14 patients with acute myocardial infarction. Systemic effects on coagulation and fibrinolysis were studied. In 1 patient, the treatment produced no biological modification, which could be explained by an increased streptokinase resistance in this patient, apparent from the sample collected before treatment. In the other patients, as expected, fibrinogen, plasminogen, alpha 2-antiplasmin and factors V and VIIIc fell dramatically, while there was an increase in serum fibrinogen degradation product concentrations. In addition, plasma fibrin derivatives increased during APSAC therapy, both in patients who had occluded or patent coronary arteries. Discrepancies were found between methods used to measure fibrinogen: with the Ellis and Stransky method, concentrations were higher than with the Clauss method; and for plasminogen, automated methods using different analysers may give higher results in some patients.
M Samama; J Conard; E Verdy; P van Dreden; G Nguyen; A Combrisson; J Acar
Related Documents :
12175665 - Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinas...
14728075 - Does magnesium have a role in the treatment of patients with coronary artery disease?
1507935 - Heart failure and electrolyte disturbances.
10488475 - Pharmacological effects of magnesium on arterial thrombosis--mechanisms of action?
21558475 - Multimarker risk model containing troponin-t, interleukin 10, myeloperoxidase and place...
8139095 - Right atrial myxoma with right to left shunt and coronary artery disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  268-74     Citation Subset:  IM    
Laboratorie Central d'Hématologie, Hôtel-Dieu, Paris.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Angiography
Fibrinolysis / drug effects*
Fibrinolytic Agents / therapeutic use*
Injections, Intravenous
Middle Aged
Myocardial Infarction / blood,  drug therapy*
Plasminogen / therapeutic use*
Streptokinase / therapeutic use*
Vascular Patency / drug effects
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre st...
Next Document:  Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and in...